Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Quantum Biopharma ( (TSE:QNTM) ) is now available.
On October 23, 2025, Quantum BioPharma announced that its licensee, Unbuzzd Wellness Inc., will host an investor webinar on October 30, 2025, to discuss its innovative beverage, unbuzzd. This product is designed to speed up alcohol metabolism and reduce hangover symptoms, backed by clinical trials showing significant improvements in alertness and reduction of intoxication effects. The webinar aims to attract investors for a $5 million fundraising effort, with no dilution for Quantum BioPharma shareholders. The announcement highlights Unbuzzd’s potential impact on the wellness market and its strategic importance to Quantum BioPharma’s portfolio.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is engaged in the research and development of various drug candidates, including Lucid-MS, a compound aimed at treating multiple sclerosis. Quantum BioPharma also retains a significant stake in Unbuzzd Wellness Inc., the company behind the beverage unbuzzd, which accelerates alcohol metabolism.
Average Trading Volume: 3,903
Technical Sentiment Signal: Sell
Current Market Cap: C$77.84M
For a thorough assessment of QNTM stock, go to TipRanks’ Stock Analysis page.